Srinand Nandakumar

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

Emma Searle, Francesco Forconi, Kim Linton et al. · Blood · 2023 · 32 citations · Full text

Medicine, Hematology, Oncology +16

A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies.

Anthony R. Mato, Alexey V. Danilov, Manish R. Patel et al. · Journal of Clinical Oncology · 2022 · 17 citations

Medicine, Oncology, Pharmacology +17

A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.

Adam Sharp, Anja Williams, Sarah P. Blagden et al. · Journal of Clinical Oncology · 2022 · 12 citations

Life Sciences, Immunology, Oncology +17